Project Grant R01HL182043
Award Date 8/1/26
Completion Date 5/31/31
Dollars Obligated $792K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the Trustees of Indiana University $516,592 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct integrative genomic analysis and develop high-dimensional risk prediction models for congenital heart defects using random field methods. The research leverages existing biospecimens and data from the National Birth Defect Prevention Studies, the Pediatric Cardiac Genomics Consortium, and the Trans-Omics for...
- The National Heart, Lung, and Blood Institute awarded Trustees of Indiana University $249,000 on July 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to examine the role of structural factors in cardiovascular disease disparities. The recipient will employ data fusion techniques to create neighborhood-level structural determinants by harmonizing administrative datasets with prospective cohort data from the Women's Health Initiative (WHI). The analysis will link WHI...
- The National Institutes of Health's National Heart, Lung and Blood Institute awarded $2,350,623 under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Minnesota on May 1, 2021 for a project concluding on April 30, 2022. The project aims to reduce childhood obesity through an individual randomized controlled trial testing combinations of ecological momentary intervention, home visiting, and video feedback delivered to 510 low-income, racially...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...
- The National Heart, Lung, and Blood Institute awarded the University of Delaware $395,382 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of visceral adipose tissue in obesity-induced endothelial dysfunction. The research, performed in Newark, Delaware, deciphers how visceral adipose tissue impairs KIR2.1 channels—critical mediators of endothelium-dependent vasodilation—by examining a mechanism involving endothelial CD36. The project...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $1,818,088 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how postnatal hypoxemia—reduced blood oxygen levels present in cyanotic congenital heart disease—impacts cardiac maturation and surgical recovery outcomes in pediatric patients. The project will examine the interaction between hypoxemia, myocardial immaturity, and postoperative complications through...
- The National Heart, Lung, and Blood Institute awarded $249,000 to The University of Texas Southwestern Medical Center on June 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund investigator-initiated research on fetal congenital heart disease and placental inflammation. Dr. Rachel Leon, an assistant professor in the Division of Neonatal-Perinatal Medicine at UT Southwestern and current NHLBI K23 awardee, will use advanced MRI techniques to investigate the influence...
- The National Heart, Lung, and Blood Institute (NHLBI), a division of the Department of Health and Human Services National Institutes of Health, awarded $753,539 to the University of Cincinnati Sponsored Research Services Division on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of CPNE5 (Copine 5) in cardiovascular barrier dysfunction and septic cardiomyopathy. The research addresses sepsis-induced heart failure through mechanistic study...
- The National Heart, Lung, and Blood Institute awarded the University of Pittsburgh $1,384,453 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the non-canonical roles of NIPBL in cardiomyocytes. The research addresses a gap in understanding why heterozygous NIPBL mutations—which account for over 60 percent of Cornelia de Lange Syndrome (CDLS) cases—lead to congenital heart disease or decreased cardiac function in at least 30 percent of CDLS...
- The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $3.095 million on August 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance understanding of genetic variation's role in congenital heart disease causality and outcomes. The award funds a program project grant structured around four synergistic research projects supported by administrative and computational cores. Project 1 deepens understanding of genetic causality of...